News

  • 19 July 2022
    Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update

    Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the completion of enrollment in its Phase 2a SAHARA proof-of-concept study using its first-generation DSR product (“DSR 1.0”) as treatment for congestive heart failure. Sequana Medical intends to extend SAHARA to treat  a small number of patients with its proprietary second-generation DSR product (“DSR 2.0”) to support the US IND filing, expected by year end.

  • 5 July 2022
    Sonendo, Inc. Welcomes Joanne Lindberg as Vice President of Sales, North America

    Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of Joanne Lindberg as Vice President of Sales, North America. As Sonendo continues to scale and further establish its leadership position within the endodontic market, Lindberg will oversee sales strategy and execution across the United States and Canada. With a focus on increasing adoption and driving utilization of the GentleWave System, she will serve as a key member of Sonendo’s commercial leadership team.

  • 28 June 2022
    Results of First Commercial Trilogy Heart Valve System Implants in EU

    JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, announced positive results from the first Trilogy Heart Valve System commercial implants for high-surgical risk patients with severe, symptomatic aortic stenosis (AS) or aortic regurgitation (AR) in Europe, initially presented at EuroPCR 2022 on May 18.

  • 17 June 2022
    Sonendo, Inc. Announces Executive Management Team Changes

    Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced two upcoming departures from its executive management team. Jacqueline Collins, vice president, general counsel, and Merhzad Khakpour, chief technology officer, will each leave the company in July for other opportunities.

  • 17 May 2022
    JenaValve Appoints Kari Moore as Chief Financial Officer

    JenaValve Technology, Inc. (“JenaValveor the “Company”), developer and manufacturer of differentiated transcatheter aortic valvereplacement (TAVR) systems, today announced the appointment of Kari Moore as theCompany’s CFO effective May 10th, 2022.